Kala Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 28.11 million compared to USD 36.5 million a year ago. Basic loss per share from continuing operations was USD 19 compared to USD 28.5 a year ago.
For the six months, net loss was USD 61.05 million compared to USD 66.91 million a year ago. Basic loss per share from continuing operations was USD 41.5 compared to USD 53 a year ago.